We are live on ! Find out more
VCNX

Vaccinex, Inc. Common Stock
VCNX

Delisted

VCNX was delisted on the 17th of December, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Vaccinex, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $45 → $0 (-$45)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$45

VCNX Hedge Fund Activity: Q1 2025 in Review

0 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Vaccinex, Inc. Common Stock (VCNX) for Q1 2025, worth a combined $0 — down 100% from $45 a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of VCNX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Barclays, exiting entirely with an estimated $45 sold.

  • 0 institutional investors held Vaccinex, Inc. Common Stock (VCNX) as of Q1 2025, down from 1 in Q4 2024.
  • Funds reported $0 of Vaccinex, Inc. Common Stock stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Vaccinex, Inc. Common Stock positions in Q1 2025 and 1 closed out, a net change of -1 holder.
  • The largest Vaccinex, Inc. Common Stock seller in Q1 2025 was Barclays, an estimated $45 sold.

Based on aggregated 13F filings for Q1 2025.